Growth-hormone secretagogues
The growth-hormone-secretagogue category covers the two main pharmacological routes to pulsatile GH release: ghrelin-receptor (GHSR-1a) agonists like Ipamorelin and GHRP-6, and GHRH-receptor analogues like Sermorelin (the historical Geref®), CJC-1295 (with and without the DAC half-life-extending modification), and the FDA-approved Tesamorelin (Egrifta®, supplied here as research-grade peptide).
IGF-1 LR3 — the engineered long-acting IGF-1 analogue with reduced binding-protein affinity — closes out the category as the most widely used IGF-1 reference standard in muscle-biology and cell-culture research.
- SKUs in class
- 7
- Median purity
- ≥ 99%
- Verified by
- Janoshik · SVK
Ipamorelin 10 mg
Selective growth-hormone secretagogue — pentapeptide.
- Form
- Lyophilised kit
- Dose
- 10 mg / vial
- Purity
- ≥ 99.0%
CJC-1295 with DAC 5 mg
Long-acting GHRH analogue with Drug Affinity Complex.
- Form
- Lyophilised kit
- Dose
- 5 mg / vial
- Purity
- ≥ 99.0%
CJC-1295 no DAC 10 mg
Short-acting GHRH (1-29) analogue — no DAC linker.
- Form
- Lyophilised kit
- Dose
- 10 mg / vial
- Purity
- ≥ 99.0%
Tesamorelin 10 mg
Approved GHRH analogue — stabilised long-acting GRF(1-44).
- Form
- Lyophilised kit
- Dose
- 10 mg / vial
- Purity
- ≥ 99.0%
Sermorelin 10 mg
GHRH(1-29) analogue — the minimum fragment with full GH-releasing activity.
- Form
- Lyophilised kit
- Dose
- 10 mg / vial
- Purity
- ≥ 99.0%
GHRP-6 10 mg
Non-selective ghrelin-receptor agonist — hexapeptide.
- Form
- Lyophilised kit
- Dose
- 10 mg / vial
- Purity
- ≥ 99.0%
IGF-1 LR3 1 mg
Modified IGF-1 — reduced IGFBP binding, ~83-residue analogue.
- Form
- Lyophilised kit
- Dose
- 1 mg / vial
- Purity
- ≥ 98.0%